Skip to main content

Branded

  • FDA approves J&J's Xarelto for stroke prevention

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for preventing stroke in patients with abnormal heart rhythm, the agency said.

    The agency announced Friday the approval of Xarelto (rivaroxaban), an anti-clotting made by J&J subsidiary Janssen Pharmaceuticals, in patients with non-valvular atrial fibrillation. The FDA approved the drug in the 10-mg strength in July for deep-vein thrombosis in patients receiving knee and hip replacement surgery. The latest approval includes 15-mg and 20-mg strengths.

  • Sentinel Capital Partners acquires WellSpring

    NEW YORK — Sentinel Capital Partners has acquired Sarasota, Fla.-based WellSpring Pharmaceutical, the private equity firm said Monday.

    Sentinel, which describes itself as investing in lower middle-market companies, said it bought the manufacturer of prescription and OTC drugs, which manufactures its products in Ontario, alongside Ancor Capital Partners. Financial terms of the deal were not disclosed.

  • Octapharma USA to reintroduce immune disorder drug

    HOBOKEN, N.J. — The Food and Drug Administration has cleared the way for the return to market of a drug for treating immunodeficiency diseases following its recall by the manufacturer in response to patients developing internal blood clots.

  • Branded generics offer new ways to reformulate drugs

    In the classic “Arabian Nights” tale of Aladdin and his magic lamp, the evil sorcerer who made Aladdin retrieve the lamp containing the genie attempts to get it back by tricking Aladdin’s wife into giving it to him by roaming through the streets offering to trade “new lamps for old.”


  • Novo Nordisk donates $50,000 to Diabetes Hands Foundation

    PRINCETON, N.J. — Novo Nordisk has donated $50,000 to an organization that raises awareness about diabetes and connects people living with it, the Danish drug maker said.

    The company said the donation, to the Diabetes Hands Foundation, was meant to recognize the Drive the Switch program, which it said had motivated more than 10,000 people to pledge to talk to loved ones and their doctors about insulin options.

  • FDA report: 35 new drugs approved in past year

    SILVER SPRING, Md. — The Food and Drug Administration has approved 35 new drugs over the past 12 months, the agency said Thursday.

  • BMS to present abstracts from Orencia studies at American College of Rheumatology meeting

    NEW YORK — Drug maker Bristol-Myers Squibb will present 20 study abstracts at the American College of Rheumatology Annual Scientific Meeting in Chicago, the company said Thursday.

    Bristol said that of those, 18 contain new data from studies of Orencia (abatacept) in patients with rheumatoid arthritis or lupus nephritis.

  • Pfizer switch of Lipitor under consideration

    NEW YORK — It's official. Pfizer will be exploring a potential switch of its blockbuster lipid-lowering drug Lipitor (atorvastatin calcium).

X
This ad will auto-close in 10 seconds